Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCUDDO LTFU
NCT07706673Phase 4Enrolling by invitation
- Sponsor
- National Cancer Institute
- Start
- Aug 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, human papillomavirus-related malignant neoplasm, sponsored by National Cancer Institute. Started Aug 2026; status: enrolling by invitation.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionhuman papillomavirus-related malignant neoplasm
Beyond the preview
Go deeper on NCT07706673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706673.